ASH1L and bone neoplasm: To deconvolute the impact of ASH1L on invading cancer cells and metastatic bone niches, we performed single-cell RNA sequencing (scRNA-seq) in control (n = 3) and ASH1L-depleted (n = 4) syngeneic bone tumors.